ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Provided By GlobeNewswire
Last update: Jun 5, 2024
Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise
